Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp KO Alfarouk, CM Stock, S Taylor, M Walsh, AK Muddathir, D Verduzco, ... Cancer cell international 15, 1-13, 2015 | 653 | 2015 |
The Warburg effect and the hallmarks of cancer L Schwartz, C T Supuran, K O Alfarouk Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2017 | 351 | 2017 |
Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question KO Alfarouk, D Verduzco, C Rauch, AK Muddathir, HHB Adil, ... Oncoscience 1 (12), 777, 2014 | 276 | 2014 |
Out of Warburg Effect: an effective cancer treatment targeting the tumor specific metabolism and dysregulated pH L Schwartz, T Seyfried, KO Alfarouk, JDV Moreira, S Fais Seminars in Cancer Biology, 2017 | 127 | 2017 |
Tumor acidity as evolutionary spite KO Alfarouk, AK Muddathir, MEA Shayoub Cancers 3 (1), 408-414, 2011 | 126 | 2011 |
The Possible Role of Helicobacter pylori in Gastric Cancer and Its Management KO Alfarouk, AHH Bashir, AN Aljarbou, AMA Ramadan, AK Muddathir, ... Frontiers in Oncology 9, 75, 2019 | 102 | 2019 |
Tumor metabolism, cancer cell transporters, and microenvironmental resistance KO Alfarouk Journal of Enzyme Inhibition and Medicinal Chemistry 31 (6), 859-866, 2016 | 91 | 2016 |
The Pentose Phosphate Pathway Dynamics in Cancer and Its Dependency on Intracellular pH KO Alfarouk, SBM Ahmed, RL Elliott, B A, SS Alqahtani, ME Ibrahim, ... Metabolites 10 (285), 2020 | 86 | 2020 |
Evolution of tumor metabolism might reflect carcinogenesis as a reverse evolution process (dismantling of multicellularity) KO Alfarouk, MEA Shayoub, AK Muddathir, GO Elhassan, AHH Bashir Cancers 3 (3), 3002-3017, 2011 | 68 | 2011 |
Riparian ecosystems in human cancers KO Alfarouk, ME Ibrahim, RA Gatenby, JS Brown Evolutionary applications 6 (1), 46-53, 2013 | 66 | 2013 |
Cellular acidification as a new approach to cancer treatment and to the understanding and therapeutics of neurodegenerative diseases S Harguindey, D Stanciu, J Devesa, K Alfarouk, RA Cardone, JDP Orozco, ... Seminars in cancer biology 43, 157-179, 2017 | 65 | 2017 |
Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review T Kolti, SJ Reshkin, C TMA, D DiMolfetta, MR Greco, KO Alfarouk, ... Cancers 14 (10), 2486, 2022 | 51 | 2022 |
Vascular measurements correlate with estrogen receptor status. M Lloyd, K Alfarouk, D Verduzco, M Bui, R Gillies, M Ibrahim, J Brown, ... BMC Cancer 14, 279, 2014 | 45 | 2014 |
Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches TMA Carvalho, D Di Molfetta, MR Greco, T Koltai, KO Alfarouk, ... Cancers 13 (23), 6135, 2021 | 42 | 2021 |
The Interplay of Dysregulated pH and Electrolyte Imbalance in Cancer KO Alfarouk, SBM Ahmed, A Ahmed, RL Elliott, ME Ibrahim, HS Ali, ... Cancers 12 (4), 898, 2020 | 42 | 2020 |
Of mitochondrion and COVID-19 KO Alfarouk, STS Alhoufie, A Hifny, L Schwartz, AS Alqahtani, ... Journal of Enzyme Inhibition and Medicinal Chemistry 36 (1), 1258-1267, 2021 | 36 | 2021 |
The Role of Sodium Hydrogen Exchanger 1 in Dysregulation of Proton Dynamics and Reprogramming of Cancer Metabolism as a Sequela RA Cardone, KO Alfarouk, RL Elliott, SS Alqahtani, SM Babikir, ... International Journal of Molecular Sciences 20 (15), 3694, 2019 | 33 | 2019 |
Doxycycline as Potential Anti-Cancer Agent I Ali, KO Alfarouk, SJ Reshkin, ME Ibrahim Anti-Cancer Agents in Medicinal Chemistry, 2017 | 30 | 2017 |
Hydrogen Ion Dynamics of Cancer and a New Molecular, Biochemical and Metabolic Approach to the Etiopathogenesis and Treatment of Brain Malignancies S Harguindey, JP Orozco, KO Alfarouk, J Devesa International Journal of Molecular Sciences 20 (17), 4278, 2019 | 17 | 2019 |
Drug Development: Stages of Drug Development GO Elhassa, KO Alfarouk Journal of Pharmacovigilance 3 (3), 2015 | 17 | 2015 |